Allogene Therapeutics (ALLO) Current Deferred Revenue (2020 - 2024)
Historic Current Deferred Revenue for Allogene Therapeutics (ALLO) over the last 5 years, with Q1 2024 value amounting to $86000.0.
- Allogene Therapeutics' Current Deferred Revenue changed 0.0% to $86000.0 in Q1 2024 from the same period last year, while for Mar 2024 it was $86000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $86000.0 for FY2023, which is 947.37% down from last year.
- According to the latest figures from Q1 2024, Allogene Therapeutics' Current Deferred Revenue is $86000.0, which was down 0.0% from $86000.0 recorded in Q4 2023.
- Allogene Therapeutics' Current Deferred Revenue's 5-year high stood at $39.0 million during Q4 2020, with a 5-year trough of $86000.0 in Q1 2023.
- Over the past 5 years, Allogene Therapeutics' median Current Deferred Revenue value was $101500.0 (recorded in 2022), while the average stood at $2.9 million.
- As far as peak fluctuations go, Allogene Therapeutics' Current Deferred Revenue tumbled by 9959.99% in 2021, and later changed by 0.0% in 2024.
- Over the past 5 years, Allogene Therapeutics' Current Deferred Revenue (Quarter) stood at $39.0 million in 2020, then tumbled by 99.6% to $156000.0 in 2021, then tumbled by 39.1% to $95000.0 in 2022, then decreased by 9.47% to $86000.0 in 2023, then changed by 0.0% to $86000.0 in 2024.
- Its last three reported values are $86000.0 in Q1 2024, $86000.0 for Q4 2023, and $86000.0 during Q3 2023.